The Goals of Treatment in AML

In the third article of this series, Bradley McGregor, MD, gives comprehensive insights on treating patients with advanced renal cell carcinoma, with a focus on treatment sequencing.

In the third article of this series, Chung-Han Lee, MD, PhD, gives an overview of non-clear cell renal cell carcinoma, discusses key clinical trial data, and looks to the future of renal cell carcinoma treatment.

In the second article of this series, Chandler H. Park, MD, a genitourinary oncologist at Norton Cancer Institute, reviews recently updated data on advanced renal cell carcinoma treatments.

The injectable formulation of nelarabine has been granted FDA approval to treatment 2 hematologic malignancies.

The phase 3 PhALLCON trial showed a trend toward event-free survival in patients with Philadelphia chromosome positive acute lymphoblastic leukemia when treated with ponatinib compared with imatinib.

In the first article of this series, Moshe Ornstein, MD, a genitourinary medical oncologist at the Cleveland Clinic, gives an overview of renal cell carcinoma and discusses the treatment landscape.